20(SO)ortho ginseng diol derivative, medicinal composition containing them and its application

A technology of protopanaxadiol and its derivatives, which is applied in the direction of drug combination, medical preparations containing active ingredients, drug delivery, etc., to achieve the effect of reducing the activity of strong antiviral and anticancer drugs

Active Publication Date: 2005-08-10
HAINAN ASIA PHARM CO LTD
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] However, the research on 20(S)-protopanaxadiol de

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 20(SO)ortho ginseng diol derivative, medicinal composition containing them and its application
  • 20(SO)ortho ginseng diol derivative, medicinal composition containing them and its application
  • 20(SO)ortho ginseng diol derivative, medicinal composition containing them and its application

Examples

Experimental program
Comparison scheme
Effect test

Example

[0054] Preparation Example 1

[0055] Preparation of 20(S)-protopanaxadiol-12β-monomethyl ether and 20(S)-protopanaxadiol-3β,12β-dimethyl ether

[0056] 0.38g 20(S)-protopanaxadiol was dissolved in 10mL DMF, and 0.10g sodium hydride (60%) was added. After the sodium hydride is completely dissolved, add 0.20 mL of methyl iodide, heat to 70°C, and react for 5 hours. Appropriate amount of water was added to the reaction solution to precipitate a white solid. The precipitated solid was filtered and dried to obtain 0.70 g. Silica gel column chromatography, eluted with chloroform, to obtain 2 components: component 1 is 0.27g oily substance, namely 20(S)-protopanaxadiol-3β,12β-dimethyl ether; component 2 is 0.19g white The solid is 20(S)-protopanaxadiol-12β-monomethyl ether.

[0057] R-OCH 3

[0058] 1 H-NMR(CDCl 3 )δ: 0.79, 0.88, 0.98, 1.11 (18Hs×4+CH 3 ),, 1.69, 1.82 (6Hs, s, ), 3.35(3H, s, -O-CH 3 ),

[0059] 5.14(1H, t, = C-H)

[0060] 13 C-NMR(CDCl 3 )δ: 130.7...

Example

[0064] Preparation Example 2

[0065] Preparation of 20(S)-protopanaxadiol-12β-monoethyl ether and 20(S)-protopanaxadiol-3β,12β-diethyl ether

[0066] 0.38g 20(S)-protopanaxadiol was dissolved in 10mL DMF, and 0.10g sodium hydride (60%) was added. After the sodium hydride is completely dissolved, add 0.20 mL of bromoethane, heat to 70°C, and react for 5 hours. Appropriate amount of water was added to the reaction solution to precipitate a white solid. The precipitated solid was filtered and dried to obtain 0.70 g. The crude product was refined by column chromatography and eluted with chloroform to obtain 2 components: component 1 was 0.13g oily substance, namely 20(S)-protopanaxadiol-3β,12β-diethyl ether; component 2 was 0.20g white The solid is 20(S)-protopanaxadiol-12β-monoethyl ether.

[0067] R-OCH 2 CH 3

[0068] 1 H-NMR(CDCl 3 )δ: 0.67, 0.81, 0.84, 0.88, 0.90, 0.98 (18H, s×6, +CH 3 ), 1.56, 1.64 (6H, s, s, ), 1.07(3H, t, -CH 3 ), 3.01, 3.71(2H, q...

Example

[0073] Preparation Example 3

[0074] Preparation of 20(S)-protopanaxadiol-12β-n-pentyl ether

[0075] 0.38g 20(S)-protopanaxadiol was dissolved in 10mL DMF, and 0.10g sodium hydride (60%) was added. After the sodium hydride is completely dissolved, 0.38 g (0.31 mL) of n-pentane bromide is added, heated to 70° C., and reacted for 5 hours. Cool to room temperature, add 50 mL of water, precipitate an oil, and let it stand overnight. The supernatant was decanted, washed once with water, the oily substance was extracted with chloroform, and the extract was dried with anhydrous magnesium sulfate. The solvent was evaporated under reduced pressure to obtain 1.05 g of light yellow oil. The crude product was purified by silica gel column chromatography and eluted with chloroform to obtain 0.38 g of the title product as a pale yellow liquid.

[0076] 1 H-NMR(CDCl 3 )δ: 0.78, 0.88, 0.95, 0.98, 1.10 (18H, s×4, +CH 3 ), 0.88(3H, t, -CH 3 ), 1.57, 1.62 (6H, s, s, ), ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An antineoplastic 20(S)-protopanoxadiol derivative and its medicinal composition for treating tumor and viral diseases are disclosed.

Description

technical field [0001] The present invention relates to 20(S)-protopanaxadiol derivatives with antitumor activity, pharmaceutical compositions containing them and applications thereof. Background technique [0002] 20(S)-Protopanaxadiol (20(S)-Dama-24-ene-3β, 12β, 20β-triol) is the main active ingredient of ginseng, protopanaxadiol group saponin R b1 , R b2 , R b3 , R c , R d , Aglycones such as saponins. Japanese Open Patent Gazette (Shao 58-13199), 20(S)-protopanaxadiol, 20(R)-protopanaxadiol, 20(S)-protopanaxatriol, 20(R)-protopanaxadiol, 20(R)-protopanaxadiol Alcohols have strong anticancer activity, and 20(S)-protopanaxadiol has the strongest anticancer activity. (Tadahideota et al.J.Pharm.Sci.1991, 80(12):1141-1143) reported that 20(S)-protopanaxadiol has more tumor inhibitory activity on melanoma than ginsenoside Rh 2 stronger. Jin Yongri et al. reported (CN1416833) that 20(S)-protopanaxadiol not only has anticancer activity, but also...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/02A61K9/08A61K9/16A61K9/20A61K9/48A61K31/704A61P31/12A61P35/00C07J9/00
Inventor 楼金张龙清张兴权
Owner HAINAN ASIA PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap